Importer of Controlled Substances; Notice of Registration, 6061-6062 [2010-2570]
Download as PDF
<![CDATA[
srobinson on DSKHWCL6B1PROD with NOTICES
Federal Register / Vol. 75, No. 24 / Friday, February 5, 2010 / Notices
for alleged environmental violations of
the Prevention of Significant
Deterioration (‘‘PSD’’) provisions of the
Act, 42 U.S.C. 7470–7492; the
nonattainment New Source Review
(‘‘nonattainment NSR’’) provisions of the
Act, 42 U.S.C. 7501–7515; and the
federally-approved and enforceable state
implementation plans, which
incorporate and/or implement the above
listed federal PSD and/or nonattainment
NSR requirements. The Complaint also
alleges violations of Title V of the Act,
42 U.S.C. §§ 7661–7661f, and Title V’s
implementing Federal and State
regulations. These violations are alleged
to have occurred at one or more of each
of the Lafarge Companies’ Portland
cement plants located in Alpena,
Michigan; Ravena, New York; Tulsa,
Oklahoma; Fredonia, Kansas; Sugar
Creek, Missouri; Buffalo, Iowa;
Paulding, Ohio; Gand Chain, Illinois;
Seattle, Washington; Whitehall,
Pennsylvania; Harleyville, South
Carolina; Atlanta, Georgia; and Calera,
Alabama.
Under the proposed settlement, the
Lafarge Companies will be required to
implement pollution control
technologies to reduce emissions of
nitrogen oxides and sulfur dioxide at
designated cement kilns and to meet
emission limits which are either set
forth in the Consent Decree or will be
set later by following procedures
specified in the Decree. In addition, the
Lafarge Companies must pay a total civil
penalty of $5,075,000. Two-thirds of
this penalty ($3,383,000) will be paid to
the United States, and the remaining
one-third will be shared among the
participating states and agencies as set
forth in the Consent Decree.
The States of Alabama, Illinois, Iowa,
Kansas, Michigan, Missouri, New York,
Ohio and the Commonwealth of
Pennsylvania Department of
Environmental Protection, the South
Carolina Department of Health and
Environmental Control, the Washington
State Department of Ecology, the
Oklahoma Department of Environmental
Quality, and the Puget Sound Clean Air
Agency have joined in this settlement as
signatories to the Consent Decree.
The Department of Justice will receive
for a period of thirty (30) days from the
date of this publication comments
relating to the Consent Decree.
Comments should be addressed to the
Assistant Attorney General,
Environment and Natural Resources
Division, and either mailed to
pubcomment-ees.enrd@usdoj.gov or
mailed to P.O. Box 7611, U.S.
Department of Justice, Washington, DC
20044–7611, and should refer to United
VerDate Nov<24>2008
16:26 Feb 04, 2010
Jkt 220001
States, et al. v. Lafarge North America,
Inc., et al., D.J. Ref. 90–5–2–1–08221.
The Consent Decree may be examined
at the Office of the United States
Attorney, Nine Executive Drive,
Fairview Heights, Illinois 62208–1344
and at U.S. EPA Region 5, 77 West
Jackson Blvd., Chicago, Illinois 60604–
3590. During the public comment
period, the Consent Decree may also be
examined on the following Department
of Justice Web site, https://
www.usdoj.gov/enrd/
Consent_Decrees.html. A copy of the
Consent Decree may also be obtained by
mail from the Consent Decree Library,
P.O. Box 7611, U.S. Department of
Justice, Washington, DC 20044–7611 or
by faxing or e-mailing a request to Tonia
Fleetwood (tonia.fleetwood@usdoj.gov),
fax number (202) 514–0097, phone
confirmation number (202) 514–1547. In
requesting a copy from the Consent
Decree Library, please enclose a check
in the amount of $38.00 (25 cents per
page reproduction cost) payable to the
U.S. Treasury or, if by e-mail or fax,
forward a check in that amount to the
Consent Decree Library at the stated
address.
Maureen Katz,
Assistant Section Chief, Environmental
Enforcement Section, Environment and
Natural Resources Division.
[FR Doc. 2010–2489 Filed 2–4–10; 8:45 am]
BILLING CODE 4410–15–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By Notice dated January 9, 2009, and
published in the Federal Register on
January 21, 2009, (74 FR 3641), Kenco
VPI, Division of Kenco Group, Inc., 350
Corporate Place, Chattanooga,
Tennessee 37419, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of Nabilone (7379), a basic
class of controlled substance listed in
schedule II.
The company plans to import the
listed controlled substance for
distribution to its customers.
One comment was received
concerning this application. The
comment states that DEA added
Schedule II and the drug code for
Nabilone (7379) to Kenco VPI’s importer
registration without the benefit of the
required legal process for modifying the
DEA registration. The comment further
states that, after Kenco VPI was properly
registered as an importer of Nabilone on
PO 00000
Frm 00122
Fmt 4703
Sfmt 4703
6061
November 1, 2006, there was no further
mention of Nabilone in any subsequent
notices of Kenco VPI’s applications or
approval of its applications published in
the Federal Register by DEA until the
application published on January 21,
2009. (74 FR 3641) The comment also
requested clarification whether Kenco
VPI imports Nabilone in finished drug
product in dosage form or in bulk active
pharmaceutical ingredient (API) form.
Finally, the comment inquires if the
aggregate national quota for Nabilone
established by DEA will be affected by
Kenco VPI’s application.
DEA’s response to the issues raised in
the comment are as follows: DEA has
already admitted that Kenco VPI’s
importer registration received Schedule
II and the drug code for Nabilone
without the benefit of the required legal
process. On August 1, 2006, a Notice of
Application (71 FR 43526) was
published for Kenco VPI in the Federal
Register. Subsequently, on November 1,
2006, a Notice of Registration (71 FR
64298) was published. These notices
addressed DEA’s issuance to Kenco
VPI’s importer registration of Schedule
II and the drug code for Nabilone
without the benefit of the required legal
process. As a result of the publication of
these notices, Kenco VPI’s importer
registration has been legally authorized
to import Nabilone, effective: November
1, 2006.
DEA rejects the comment’s assertion
that, between November 1, 2006 and
January 21, 2009, there was no further
mention of Nabilone in any subsequent
notices of Kenco VPI’s applications or
approval of its applications published in
the Federal Register by DEA. This
assertion is incorrect. Four notices were
published between November 1, 2006
and January 21, 2009 as follows: (71 FR
66974, November 17, 2006), (72 FR
8792, February 27, 2007), (73 FR 14840,
March 19, 2008), (73 FR 31510, June 2,
2008). Each of these notices mentions
Nabilone.
With regard to the comment’s request
for clarification of whether Kenco VPI
imports Nabilone in finished drug
product in dosage form or in bulk active
pharmaceutical ingredient (API) form,
the company imports finished drug
products in dosage form only. Kenco
VPI does not import Nabilone in bulk
active pharmaceutical ingredient (API)
form. Since there are no domestic
sources of Nabilone in finished drug
product form available within the
United States and since the product
which Kenco VPI imports has been
approved for medical use within the
United States by the U.S. Food and Drug
Administration, DEA finds no reason to
reject Kenco VPI’s application. The
E:\FR\FM\05FEN1.SGM
05FEN1
6062
Federal Register / Vol. 75, No. 24 / Friday, February 5, 2010 / Notices
aggregate national quota for Nabilone
established by DEA will not be affected
by this application of Kenco VPI since
the company imports Nabilone in
finished drug product form only.
DEA has considered the factors in 21
U.S.C. 823(a) and 952(a) and determined
that the registration of Kenco VPI to
import the basic class of controlled
substance is consistent with the public
interest, and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971, at this time. DEA has
investigated Kenco VPI to ensure that
the company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and § 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
Dated: January 29, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–2570 Filed 2–4–10; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Dated: January 27, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Drug Enforcement Administration
srobinson on DSKHWCL6B1PROD with NOTICES
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2), authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on April
3, 2009, Wildlife Laboratories, 1401 Duff
Drive, Suite 400, Fort Collins, Colorado
80524, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as an importer of
Etorphine Hydrochloride (9059), a basic
class of controlled substance listed in
schedule II.
The company plans to import the
listed controlled substance for sale to its
customers.
VerDate Nov<24>2008
16:26 Feb 04, 2010
Jkt 220001
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
may file comments or objections to the
issuance of the proposed registration
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43,
and in such form as prescribed by 21
CFR 1316.47.
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than March 8, 2010.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substance in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a), 21 U.S.C. 823(a), and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
[FR Doc. 2010–2575 Filed 2–4–10; 8:45 am]
BILLING CODE 4410–09–P
Drug
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Cocaine (9041) .............................
Schedule
I
I
I
The Institute will manufacture small
quantities of cocaine and marihuana
derivatives for use by their customers in
analytical kits, reagents, and reference
standards as directed by the National
Institute on Drug Abuse.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Research Triangle Institute to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
investigated Research Triangle Institute
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: January 25, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–2578 Filed 2–4–10; 8:45 am]
BILLING CODE 4410–09–P
MARINE MAMMAL COMMISSION
Notice of Meeting
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances Notice of Registration
By Notice dated August 21, 2009, and
published in the Federal Register on
September 8, 2009, (74 FR 46232),
Research Triangle Institute, Kenneth H.
Davis Jr., Hermann Building, East
Institute Drive, P.O. Box 12194,
Research Triangle, North Carolina
27709, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in
schedules I and II:
PO 00000
Frm 00123
Fmt 4703
Sfmt 4703
Time and Date: The Marine Mammal
Commission will conduct a review of
the potential effects of human activities,
including aquaculture operations, on
harbor seals in Drake’s Estero, Mann
County, California, on 21–24 February
2010 from 9 a.m. to approximately 6
p.m.
Place: The Red Barn, Point Reyes
National Seashore, I Bear Valley Road,
Point Reyes Station, CA 94956.
Status: Sessions on Sunday, February
21, and Tuesday and Wednesday,
February 23–24 will be open to the
public. Public participation will be
allowed as time permits and as
determined to be desirable by the
meeting chairperson. There will be no
public meeting on Monday, February
22.
E:\FR\FM\05FEN1.SGM
05FEN1
]]>Agencies
[Federal Register Volume 75, Number 24 (Friday, February 5, 2010)]
[Notices]
[Pages 6061-6062]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-2570]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Registration
By Notice dated January 9, 2009, and published in the Federal
Register on January 21, 2009, (74 FR 3641), Kenco VPI, Division of
Kenco Group, Inc., 350 Corporate Place, Chattanooga, Tennessee 37419,
made application by renewal to the Drug Enforcement Administration
(DEA) to be registered as an importer of Nabilone (7379), a basic class
of controlled substance listed in schedule II.
The company plans to import the listed controlled substance for
distribution to its customers.
One comment was received concerning this application. The comment
states that DEA added Schedule II and the drug code for Nabilone (7379)
to Kenco VPI's importer registration without the benefit of the
required legal process for modifying the DEA registration. The comment
further states that, after Kenco VPI was properly registered as an
importer of Nabilone on November 1, 2006, there was no further mention
of Nabilone in any subsequent notices of Kenco VPI's applications or
approval of its applications published in the Federal Register by DEA
until the application published on January 21, 2009. (74 FR 3641) The
comment also requested clarification whether Kenco VPI imports Nabilone
in finished drug product in dosage form or in bulk active
pharmaceutical ingredient (API) form. Finally, the comment inquires if
the aggregate national quota for Nabilone established by DEA will be
affected by Kenco VPI's application.
DEA's response to the issues raised in the comment are as follows:
DEA has already admitted that Kenco VPI's importer registration
received Schedule II and the drug code for Nabilone without the benefit
of the required legal process. On August 1, 2006, a Notice of
Application (71 FR 43526) was published for Kenco VPI in the Federal
Register. Subsequently, on November 1, 2006, a Notice of Registration
(71 FR 64298) was published. These notices addressed DEA's issuance to
Kenco VPI's importer registration of Schedule II and the drug code for
Nabilone without the benefit of the required legal process. As a result
of the publication of these notices, Kenco VPI's importer registration
has been legally authorized to import Nabilone, effective: November 1,
2006.
DEA rejects the comment's assertion that, between November 1, 2006
and January 21, 2009, there was no further mention of Nabilone in any
subsequent notices of Kenco VPI's applications or approval of its
applications published in the Federal Register by DEA. This assertion
is incorrect. Four notices were published between November 1, 2006 and
January 21, 2009 as follows: (71 FR 66974, November 17, 2006), (72 FR
8792, February 27, 2007), (73 FR 14840, March 19, 2008), (73 FR 31510,
June 2, 2008). Each of these notices mentions Nabilone.
With regard to the comment's request for clarification of whether
Kenco VPI imports Nabilone in finished drug product in dosage form or
in bulk active pharmaceutical ingredient (API) form, the company
imports finished drug products in dosage form only. Kenco VPI does not
import Nabilone in bulk active pharmaceutical ingredient (API) form.
Since there are no domestic sources of Nabilone in finished drug
product form available within the United States and since the product
which Kenco VPI imports has been approved for medical use within the
United States by the U.S. Food and Drug Administration, DEA finds no
reason to reject Kenco VPI's application. The
[[Page 6062]]
aggregate national quota for Nabilone established by DEA will not be
affected by this application of Kenco VPI since the company imports
Nabilone in finished drug product form only.
DEA has considered the factors in 21 U.S.C. 823(a) and 952(a) and
determined that the registration of Kenco VPI to import the basic class
of controlled substance is consistent with the public interest, and
with United States obligations under international treaties,
conventions, or protocols in effect on May 1, 1971, at this time. DEA
has investigated Kenco VPI to ensure that the company's registration is
consistent with the public interest. The investigation has included
inspection and testing of the company's physical security systems,
verification of the company's compliance with state and local laws, and
a review of the company's background and history. Therefore, pursuant
to 21 U.S.C. 952(a) and Sec. 958(a), and in accordance with 21 CFR
1301.34, the above named company is granted registration as an importer
of the basic class of controlled substance listed.
Dated: January 29, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2010-2570 Filed 2-4-10; 8:45 am]
BILLING CODE 4410-09-P
